Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.

20 brokers have issued 12-month price objectives for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they predict the company's stock price to reach $245.74 in the next year. This suggests a possible upside of 22.7% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.

Alnylam Pharmaceuticals' stock was trading at $237.65 at the beginning of the year. Since then, ALNY stock has decreased by 15.7% and is now trading at $200.32.
View the best growth stocks for 2023 here.

Alnylam Pharmaceuticals saw a decrease in short interest in March. As of March 15th, there was short interest totaling 4,930,000 shares, a decrease of 8.5% from the February 28th total of 5,390,000 shares. Based on an average daily volume of 781,100 shares, the short-interest ratio is presently 6.3 days.
View Alnylam Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our ALNY earnings forecast.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its earnings results on Thursday, February, 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.45. The biopharmaceutical company had revenue of $335.04 million for the quarter, compared to analyst estimates of $312.45 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 1,287.80% and a negative net margin of 109.04%. The firm's quarterly revenue was up 29.6% on a year-over-year basis. During the same period in the prior year, the company earned ($2.16) earnings per share.

ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), VanEck Biotech ETF (BBH), American CenturyFocused Dynamic Growth ETF (FDG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC) and VictoryShares Nasdaq Next 50 ETF (QQQN).

Alnylam Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.48 billion.

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNY stock can currently be purchased for approximately $200.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $24.87 billion and generates $1.04 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($9.29) on an earnings per share basis.

The company employs 2,002 workers across the globe.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.